Investment will support commercialization of GPX and ULTRA Embolic Devices and development of IMPASS neurovascular platform.
Canyon Labs strengthens its commitment to medical device manufacturers with strategic, direct-access leadership investments.
Southern Metrics is led by Chris Lyons, its Chief Executive Officer, an experienced medical technology executive and strategic advisor who has served on the SINTX Board of Directors since April 2025.
Independent industry recognition highlights the Company’s revolutionary immunotherapy platform and growing momentum in precision cancer treatment.
Global medical device quality executive brings more than 30 years of experience building high-performing organizations, advancing quality excellence and supporting scalable growth.
Company also completes proof of concept for the first blood-borne test for Ebola on Co-Dx PCR Pro ® instrument.
ReNU syndrome was discovered in 2024 and there are no medicines approved for the condition.
Company completes design and in-vitro validation of a single Smart mRNA that disguises cancer as multiple viral infections simultaneously to activate pre-existing T-cell immunity.
Preclinical data show HT-4253 reduces neuroinflammation and tau pathology; a second details a Phase 2a biomarker trial in pre-symptomatic APOE4 carriers via UAE genomics.
Purchase orders from multiple contract manufacturing customers have a combined value of more than $3.2M.
CAP accreditation is widely recognized as a mark of laboratory quality and operational excellence.
Brand consolidation strengthens Renew’s ability to move advanced molecular technologies from discovery to clinical implementation.
KyphoLift is gaining attention as hospitals and imaging centers prepare for federal accessibility requirements.
Marks an important milestone with a ribbon-cutting ceremony celebrating the completion of an expansive new distribution center.
Trial Reports 99% Successful Occlusion of Flow with 40 Investigators Delivering the New Embolic Through 20 Different Catheters.
Workshop brings together national TB programs, researchers, donors, and technical agencies from 21 countries to advance implementation of WHO-recommended near-point-of-care diagnostics.
INTEGUMENT-INFANT showed 49.1% achieving vIGA-AD clear/almost clear at week 4 and 27.3% meeting vIGA-AD Success, alongside rapid pruritus improvement.
resentation will highlight recent scientific advances and future opportunities to accelerate discovery and development of medicines for neurodegenerative diseases.
Physician and U.S. Rep. Mike Kennedy (R-UT) toured the Edwards Lifesciences plant in Draper, UT, on Wednesday.
Collaboration connects European development expertise with U.S. manufacturing to give medtech innovators a seamless path from concept to commercialization for safety-critical medical devices.
Newman presents evidence that direct contracting can lower healthcare costs, improve transparency, and return savings to workers.
More than 1,400 patients enrolled across 9 clinical sites; analytical performance testing included 27 individual studies and over 10,000 PCR test cup runs.
Project designed to support supply chain continuity for customers relying on the company for their cell culture needs.
The new molecular panels are designed to detect up to 22 pathogens in one hour with enhanced norovirus detection.
Alzheimer’s disease is one of the world’s most pressing health challenges, affecting more than 55 million people globally; a number expected to nearly triple by 2050.
Collaboration strengthens Ratio’s long-term isotope supply strategy for clinical development and future pipeline growth.
SkinTE® would be the first new biologic commercially available in the U.S. for the treatment of a common chronic wound indication in nearly 30 years, if approved.
Landmark study of 2,470 patients across two U.S. health systems demonstrates sustained risk-stratified improvements in kidney function, increases in guideline-directed therapy uptake, and – for the first time – measurable reduction in individual patient risk trajectories over 24 months
Indication expansion addresses a major pediatric gap where topical corticosteroids are commonly used off-label yet constrained by sensitive-site and long-term continuous-use limitations.
Virtual health platform offers an additional pathway to care for the more than 45 million people in the U.S. living with eczema, seborrheic dermatitis, and plaque psoriasis.
ASE 2026 data support further development of MVT-100 in pivotal trials.
The automated PCR test provides results in 20 minutes to help clinicians diagnose common causes of vaginitis during a patient visit.
